Table 1. Patient Characteristics (N = 55).
| Demographic and Baseline Characteristics | No. (%) |
|---|---|
| Age, y | |
| Median | 60 |
| Range | 31-76 |
| Sex | |
| Men | 26 (47.3) |
| Women | 29 (52.7) |
| KPS score | |
| 60 | 2 (3.6) |
| 70 | 2 (3.6) |
| 80 | 37 (67.3) |
| 90 | 8 (14.5) |
| 100 | 6 (10.9) |
| EGFR status* | |
| 11 | 2 (3.6) |
| 21 | 6 (10.9) |
| 31 | 47 (85.5) |
| Histology | |
| Adenocarcinoma | 36 (65.5) |
| Squamous cell carcinoma | 12 (22) |
| Other/unknown | 7 (13) |
| Prior therapy for lung cancer | |
| Chemotherapy | 55 (100.0) |
| Immunotherapy | 2 (3.6) |
| Radiotherapy | 26 (47.3) |
KPS indicates Karnofsky performance status; EGFR, epidermal growth factor receptor.
*
EGFR staining intensity guidelines: 1+, a faint/barely perceptible membrane staining is detected in more than 10% of the tumor cells; 2+, a weak to moderate membrane staining is present, completely surrounding the cells in more than 10% of the tumor cells; 3+, a strong complete membrane staining is observed in more than 10% of the tumor cells.